CBT

Long-Term Effectiveness and Cost-Effectiveness of Videoconference-Delivered Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder, Panic Disorder, and Social Anxiety Disorder in Japan: One-Year Follow-Up of a Single-Arm Trial

Citation
Matsumoto K, Hamatani S, Nagai K, Sutoh C, Nakagawa A, Shimizu E. Long-Term Effectiveness and Cost-Effectiveness of Videoconference-Delivered Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder, Panic Disorder, and Social Anxiety Disorder in Japan: One-Year Follow-Up of a Single-Arm Trial JMIR Ment Health 2020;7(4):e17157 DOI: 10.2196/17157
Publication Date

ABSTRACT

Background: Face-to-face individual cognitive behavioral therapy (CBT) and internet-based CBT (ICBT) without videoconferencing are known to have long-term effectiveness for obsessive-compulsive disorder (OCD), panic disorder (PD), and social anxiety disorder (SAD). However, videoconference-delivered CBT (VCBT) has not been investigated regarding its long-term effectiveness and cost-effectiveness.

National Trainers Trained on Universal Treatment Curriculum (UTC) 12 and 15 in Turkmenistan

From 15-21 July 2019 team of national trainers from Turkmenistan attended the National Training of Trainers held in Ashgabat, Turkmenistan. There were 12 representatives of drug dependence treatment service of the Ministry of Health of Turkmenistan and non-profit organizations (ICAP 1 holders) trained on the two following courses of Advanced Level UTC: Course 12: Cognitive-Behavioral Therapy Course 15: Managing Co-Occurring Disorders Trainer-led presentations, small-group and reflective exercises, role-plays and case study discussions helped participants to

Nabiximols Combined with Motivational Enhancement/Cognitive Behavioral Therapy for the Treatment of Cannabis Dependence

Citation
Trigo JM, Soliman A, Quilty LC, Fischer B, Rehm J, Selby P, et al. (2018) Nabiximols combined with motivational enhancement/ cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. PLoS ONE 13(1): e0190768. https://doi.org/ 10.1371/journal.pone.0190768
Publication Date

Abstract

Background

The current lack of pharmacological treatments for cannabis use disorder (CUD) warrants novel approaches and further investigation of promising pharmacotherapy. We previously showed that nabiximols (27 mg/ml Δ9-tetrahydrocannabinol (THC)/ 25 mg/ml cannabidiol (CBD), Sativex®) can decrease cannabis withdrawal symptoms.